Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V 1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The limbic localization of the arginine vasopressin V 1b receptor has prompted speculation as to a potential role of this receptor in the control of emotional processes. To investigate this possibility, we have studied the behavioral effects of SSR149415, the first selective and orally active non-peptide antagonist of vasopressin V 1b receptors, in a variety of classical (punished drinking, elevated plus-maze, and light/dark tests) and atypical (fear/anxiety defense test battery and social defeat-induced anxiety) rodent models of anxiety, and in two models of depression [forced swimming and chronic mild stress (CMS)]. When tested in classical tests of anxiety, SSR149415 produced anxiolytic-like activity at doses that ranged from 1 to 30 mg/kg (i.p. or p.o.), but the magnitude of these effects was overall less than that of the benzodiazepine anxiolytic diazepam, which was used as a positive control. In contrast, SSR149415 produced clear-cut anxiolytic-like activity in models involving traumatic stress exposure, such as the social defeat paradigm and the defense test battery (1–30 mg/kg, p.o.). In the forced swimming test, SSR149415 (10–30 mg/kg, p.o.) produced antidepressant-like effects in both normal and hypophysectomized rats. Moreover, in the CMS model in mice, repeated administration of SSR149415 (10 and 30 mg/kg, i.p.) for 39 days improved the degradation of the physical state, anxiety, despair, and the loss of coping behavior produced by stress. These findings point to a role for vasopressin in the modulation of emotional processes via the V 1b receptor, and suggest that its blockade may represent a novel avenue for the treatment of affective disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
Pellow, S., Chopin, P., File, S. E., & Briley, M. (1985) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(85)90031-7 · Cited by 5,822
Depression: a new animal model sensitive to antidepressant treatments
PORSOLT, R. D., LE PICHON, M., & JALFRE, M. (1977) · Nature · doi:10.1038/266730a0 · Cited by 4,451
Neurocircuitry of stress: central control of the hypothalamo–pituitary–adrenocortical axis
Herman, J. P., & Cullinan, W. E. (1997) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10069-2 · Cited by 2,270
Chronic mild stress-induced anhedonia: A realistic animal model of depression
Willner, P., Muscat, R., & Papp, M. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80194-0 · Cited by 1,160
A simple and reliable conflict procedure for testing anti-anxiety agents
Vogel, J. R., Beer, B., & Clody, D. E. (1971) · Psychopharmacologia · doi:10.1007/bf00403989 · Cited by 841
Ethopharmacological analysis of rat behavior on the elevated plus-maze
Cruz, A. P. M., Frei, F., & Graeff, F. G. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90472-3 · Cited by 823
de Vries, G. J., & Buijs, R. M. (1983) · Brain Research · doi:10.1016/0006-8993(83)90855-7 · Cited by 565
Molecular cloning and expression of a rat Via arginine vasopressin receptor
Morel, A., O'Carroll, A.-M., Brownstein, M. J., & Lolaft, S. J. (1992) · Nature · doi:10.1038/356523a0 · Cited by 477
Animal models for the study of anti-anxiety agents: A review
Treit, D. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90046-6 · Cited by 450
Miczek, K. A. (1979) · Psychopharmacology · doi:10.1007/bf00426664 · Cited by 397
Research works printed but not linked: 3
- D De Wied J Endocrinol 48, xlv–xlvi (1970).
- R Dantzer, R M Bluthe Crit Rev Neurobiol 6, 243–255 (1992).
- J Simiand, P E Keane, M C Barnouin, M Keane, P Soubrié, G Le Fur Fundam Clin Pharmacol 7, 413–427 (1993).
Cited by
Items 201–300 of 524
Mouse models of fear-related disorders: Cell-type-specific manipulations in amygdala
Gafford, G. M., & Ressler, K. J. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.019 · Cited by 43
“A variety of studies have shown that VP enhances and OT decreases anxiety and fear behavior (61-66).”
Laugeray, A., Launay, J.-M., Callebert, J., Mutlu, O., Guillemin, G. J., Belzung, C., & Barone, P. R. (2016) · PLOS ONE · doi:10.1371/journal.pone.0164337 · Cited by 40
Oost, T. K., Backfisch, G., Bhowmik, S., van Gaalen, M. M., Geneste, H., Hornberger, W., Lubisch, W., Netz, A., Unger, L., & Wernet, W. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.03.012 · Cited by 48
Neuropeptides in Anxiety Modulation
Landgraf, R. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-28082-0_12 · Cited by 48
Dournes, C., Beeské, S., Belzung, C., & Griebel, G. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.07.019 · Cited by 49
Self-citationDannenhoffer, C. A., Kim, E. U., Saalfield, J., Werner, D. F., Varlinskaya, E. I., & SPEAR, L. P. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5003-8 · Cited by 46
Zhou, Y., Bendor, J., Yuferov, V. P., Schlussman, S. D., Ho, A., & Kreek, M. J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.05.032 · Cited by 45
Thompson, R. R., Walton, J. C., Bhalla, R., George, K. C., & Beth, E. H. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06210.x · Cited by 41
“, 1998; Everts & Koolhaas, 1999), the bulk of evidence indicates that VP is anxiogenic (Landgraf et al., 1995; Liebsch et al., 1996; Griebel et al., 2002; Bielsky et al., 2004, 2005), and it is possible that some of the influences of VP on social behavior, particularly non-aggressive social investigation, are a second…”
BackgroundGołyszny, M. J., Obuchowicz, E., & Zielinski, M. W. (2021) · Neuropeptides · doi:10.1016/j.npep.2021.102216 · Cited by 44
Oxytocin and MDMA (‘Ecstasy’) enhance social reward in rats
Ramos, L., Hicks, C., Caminer, A., Goodwin, J., & McGregor, I. S. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3899-9 · Cited by 44
“The action of AVP on V1B receptors increases anxiety-related behaviours in mice (Egashira et al. 2007; Griebel et al. 2002) and rats (Bowen and McGregor 2014) leading to defensive aggregation.”
BackgroundPournajafi‐Nazarloo, H., Kenkel, W. M., Mohsenpour, S. R., Sanzenbacher, L., Saadat, H., Partoo, L., Yee, J. R., Azizi, F., & Carter, C. S. (2013) · Peptides · doi:10.1016/j.peptides.2013.02.007 · Cited by 44
Vasopressin: A Review of Therapeutic Applications
Holt, N. F., & Haspel, K. L. (2009) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2009.09.006 · Cited by 44
Kessler, M. S., Murgatroyd, C., Bunck, M., Czibere, L., Frank, E., Jacob, W., Horvath, C., Muigg, P., Holsboer, F., Singewald, N., et al. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05917.x · Cited by 44
“An anxiogenic role of AVP has recently been confirmed in several species, including mice, rats, voles and humans (Griebel et al., 2002; Bielsky et al., 2004; Hammock et al., 2005; Storm & Tecott, 2005; Landgraf, 2006; Thompson et al., 2006).”
BackgroundThe acute intoxicating effects of ethanol are not dependent on the vasopressin 1a or 1b receptors
Caldwell, H. K., Stewart, J., Wiedholz, L. M., Millstein, R. A., Iacangelo, A. L., Holmes, A., Young, W. S., & Wersinger, S. R. (2006) · Neuropeptides · doi:10.1016/j.npep.2006.08.001 · Cited by 44
Cid-Jofré, V., Moreno, M., Reyes-Parada, M. I., & Renard, G. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222112077 · Cited by 43
Neuropeptide and Sigma Receptors as Novel Therapeutic Targets for the Pharmacotherapy of Depression
Paschos, K. A., Veletza, S. V., & Chatzaki, Ε. (2009) · CNS Drugs · doi:10.2165/11310830-000000000-00000 · Cited by 43
Liu, X., Tribollet, E., Ogier, R., Barberis, C., & Raggenbass, M. (2003) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2003.02625.x · Cited by 38
“Our data also suggest that lumbar motoneurons are devoid of functional V1b receptors, although the presence in the brain of this class of receptors has been recently reported (Vaccari et al., 1998; Griebel et al., 2002).”
BackgroundSocial Context, Stress, Neuropsychiatric Disorders, and the Vasopressin 1b Receptor
Caldwell, H. K., Aulino, E. A., Rodriguez, K. M., Witchey, S. K., & Yaw, A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00567 · Cited by 40
“…rats and mice, treatment with SSR149415 results in fewer defensive attacks in a defense battery, less time spent immobile in a forced swim test, more foot shocks in a punished drinking task, and more open arm entries in an elevated plus maze (Griebel et al., 2002; Serradeil-Le Gal et al., 2003).”
BackgroundAnisman, H., Prakash, P., Merali, Z., & Poulter, M. O. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.04.002 · Cited by 42
Social dominance in male vasopressin 1b receptor knockout mice
Caldwell, H. K., Dike, O. E., Stevenson, E. L., Storck, K., & Young, W. S. (2010) · Hormones and Behavior · doi:10.1016/j.yhbeh.2010.03.008 · Cited by 34
“After the cloning (Lolait et al., 1995; Saito et al., 1995) and pharmacological characterization (Blanchard et al., 2005; Griebel et al., 2002) of the Avpr1b, Avpr1b knockout (Avpr1b −/−) mice were generated (Wersinger et al., 2006; Wersinger et al., 2002).”
BackgroundNelson, B. S., Sequeira, M. K., & Schank, J. R. (2018) · Addiction Biology · doi:10.1111/adb.12494 · Cited by 40
“Importantly, it has been found in some studies that alcohol consumption can normalize baseline differences in gene expression in some alcohol preferring rat models (Hansson et al. 2007).”
BackgroundHerbkines Increases Physical Stamina in Mice
Koo, H., Lee, J.-K., Hong, S., & Kim, H. (2004) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.27.117 · Cited by 41
Farvolden, P., Kennedy, S. H., & Lam, R. W. M. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.65 · Cited by 41
Spiga, F., Harrison, L. R., Wood, S., Knight, D. M., MacSweeney, C. P., Thomson, F., Craighead, M., & Lightman, S. L. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0421 · Cited by 40
Fodor, A., Kovács, K., Balázsfi, D., Klausz, B., Pintér, O., Demeter, K., Daviu, N., Rabasa, C., Rotllant, D., Nadal, R. A., et al. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.041 · Cited by 40
Unpredictable chronic mild stress in mice
Surget, A., & Belzung, C. (2008) · Enlighten: Publications (University of Glasgow) · Cited by 40
Non-Monoamine-Based Approach for the Treatment of Depression and Anxiety Disorders
Chaki, S., Okubo, T., & Sekiguchi, Y. (2006) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488906775245318 · Cited by 39
Guillon, G., Derick, S., Pena, A., Cheng, L. L., Stoev, S., Seyer, R., Morgat, J. L., Barberis, C., Gal, C. S., Wagnon, J., et al. (2004) · Journal of Neuroendocrinology · doi:10.1111/j.0953-8194.2004.01163.x · Cited by 35
Self-citationPena, A., Murat, B., Trueba, M., Ventura, M. A., Bertrand, G., Cheng, L. L., Stoev, S., Szeto, H. H., Wo, N., Brossard, G., et al. (2007) · Endocrinology · doi:10.1210/en.2006-1633 · Cited by 37
New drug targets in the signaling pathways activated by antidepressants
Páez-Pereda, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.03.017 · Cited by 39
The Role of Peptides in Treatment of Psychiatric Disorders
Holsboer, F. (2003) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6020-6_2 · Cited by 39
Vasopressin and alcohol: a multifaceted relationship
Harper, K. M., Knapp, D. J., Criswell, H. E., & Breese, G. R. (2018) · Psychopharmacology · doi:10.1007/s00213-018-5099-x · Cited by 38
“Systemic administration of V1b receptor antagonists also alters non-stress-related performance on elevated plus maze, light–dark box, punished drinking conflict test, conditioned lick suppression, social interaction test, and four-plate test (Griebel et al. 2002; Hodgson et al. 2007, 2014; Iijima et al. 2014; Overstre…”
MethodInfluentialEnhanced effect of neuropeptide Y on food intake caused by blockade of the V1A vasopressin receptor
Aoyagi, T., Kusakawa, S., Sanbe, A., Hiroyama, M., Fujiwara, Y., Yamauchi, J., & Tanoue, A. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.09.017 · Cited by 38
Engin, E., & Treit, D. (2008) · Neuropeptides · doi:10.1016/j.npep.2008.04.004 · Cited by 38
Stress-related depression: Neuroendocrine, genetic, and therapeutical aspects
Bosch, O. G., Seifritz, E., & Wetter, T. C. (2012) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2012.665477 · Cited by 38
“In vitro and animal studies indicate that several specific GR antagonists and a highly selective AVP (V1B) receptor antagonist could have stress protective and antidepressant effects (Bachmann et al. 2003; Griebel et al. 2002; Serradeil-Le Gal et al. 2002).”
BackgroundPost-dexamethasone arginine vasopressin levels in patients with severe mood disorders
Watson, S., Gallagher, P., Ferrier, I. N., & Young, A. H. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.08.001 · Cited by 37
Neuroscience of opiates for addiction medicine
Zhou, Y., & Leri, F. (2015) · Progress in brain research · doi:10.1016/bs.pbr.2015.09.001 · Cited by 37
Cheng, L. L., Stoev, S., Manning, M., Derick, S., Pena, A., Mimoun, M. B., & Guillon, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030611c · Cited by 32
Alcohol: A stimulant activating brain stress responsive systems with persistent neuroadaptation
Zhou, Y., & Kreek, M. J. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.044 · Cited by 36
“…rodent models: [a] acute stress increases extracellular AVP levels in the rat amygdala (Wigger et al., 2004); and [b] activation of AVP V1b receptors underlie anxiety-like and depression-like behaviors (Griebel et al., 2002; Serradeil-Le Gal et al., 2002; Salome et al., 2006; Roper et al., 2011).”
MethodBaumeister, D., Lightman, S. L., & Pariante, C. M. (2016) · Psychopathology Review · doi:10.5127/pr.034413 · Cited by 36
“Further developments hypothesised vasopressin receptor 1b antagonists may have a role in the treatment of depression (Griebel et al., 2002), however as of yet the potential of these agents remains unclear: in three double-blind RCTs utilising the V1b receptor antagonist SSR149415, only one found significant results on…”
BackgroundPsychiatric Disorders - Trends and Developments
(2011) · InTech eBooks · doi:10.5772/2330 · Cited by 35
Gal, C. S.-L., Raufaste, D., Derick, S., Blankenstein, J., Allen, J., Pouzet, B., Pascal, M., Wagnon, J., & Ventura, M. A. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00062.2007 · Cited by 35
“in rodents and exerts marked antidepressant-like activity in several predictive animal models (39, 16).”
BackgroundSelf-citationStojicic, S., Milutinović‐Smiljanić, S., Šarenac, O., Milosavljević, S., Paton, J. F. R., Murphy, D., & Japundžić‐Žigon, N. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.013 · Cited by 35
“For instance, intraseptal application of the V1b antagonist (SSR149415) has been shown to induce antidepressive behaviour (Griebel et al., 2002; Serradeil-Le Gal et al., 2005; Stemmelin et al., 2005), while down regulation of V1a receptors in the septum was also reported to reduce anxiety (Landgraf…”
BackgroundUrani, A., Philbert, J., Cohen, C., & Griebel, G. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.019 · Cited by 35
“…elevation of plasma ACTH, and had anxiolytic and antidepressant-like effect in various animalmodels (Alonso et al., 2003; Claustre et al., 2006;Griebel et al., 2002a; IijimaandChaki, 2007; Louis et al., 2006; Overstreet and Griebel, 2004; Overstreet and Griebel, 2005; Serradeil-Le Gal et al.,…”
BackgroundResultInfluentialSelf-citationMilutinović‐Smiljanić, S., Murphy, D., & Japundžić‐Žigon, N. (2006) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00764.2005 · Cited by 35
“It is generally assumed that because of their ubiquitous distribution in the brain, V1a receptors mediate all central effects of VP, including autonomic cardiovascular control (30, 32), while V1b receptors are invoked in stress response and control of ACTH release (1, 11).”
BackgroundVasopressin V1B receptor antagonists as potential antidepressants
Chaki, S. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab013 · Cited by 34
Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review
Fischler, P. V., Soyka, M., Seifritz, E., & Mutschler, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927703 · Cited by 34
“SSR149415 is a selective and orally-active non-peptide vasopressin type 1B receptor antagonist (V1B antagonist) that has shown anxiolytic and antidepressant effects in preliminary rodent model trials (Griebel et al., 2002; Overstreet and Griebel, 2005).”
BackgroundMOSTAFA, M., Disouky, A., & Lazarov, O. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00580 · Cited by 34
“Similarly, under chronic treatment conditions, CRHR1 and V1b receptor antagonists [183,186], improved de fi cits in neurogenesis caused by chronic mild stress [187].”
Advances in novel molecular targets for antidepressants
Wang, Q., & Dwivedi, Y. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110041 · Cited by 34
Rafiei, D., & Kolla, N. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031047 · Cited by 34
“The physical state of the coat of the animal is used to assess the animal’s grooming practices, which reflect hygiene and self-care practices that are sometimes neglected in humans with MDD [76].”
BackgroundZhou, Y., Leri, F., Cummins, E., & Kreek, M. J. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.11.002 · Cited by 34
“Also, activation of V1b receptor pathways in the amygdala has been found to be an important step in the neurobiology of stress-related behaviors [15, 34] and alcohol dependence in rodent models [35].”
BackgroundVasopressin Inhibits LTP in the CA2 Mouse Hippocampal Area
Chafai, M., Corbani, M., Guillon, G., & Desarménien, M. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049708 · Cited by 32
“Rats selected for high anxiety exhibit overexpression of AVP [16] and administration of AVP receptors antagonists decreases anxiety and depressive-like behaviors in rodents (see [4,17,18].”
BackgroundBreuer, M. E., van Gaalen, M. M., Wernet, W., Claessens, S. E. F., Oosting, R. S., Behl, B., Korte, S. M., Schoemaker, H., Gross, G., Olivier, B., et al. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0336-1 · Cited by 34
Iijima, M., & Chaki, S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.12.008 · Cited by 34
Silk Amino Acids Improve Physical Stamina and Male Reproductive Function of Mice
Shin, S., Yeon, S., Park, D., Oh, J., Kang, H., Kim, S., Joo, S. S., Lim, W.-T., Lee, J., Choi, K., et al. (2010) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.33.273 · Cited by 34
SSRI Augmentation by 5-Hydroxytryptophan Slow Release: Mouse Pharmacodynamic Proof of Concept
Jacobsen, J. P. R., Rudder, M. L., Roberts, W. L., Royer, E. L., Robinson, T. J., Oh, A., Spasojević, I., Sachs, B. D., & Caron, M. G. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.35 · Cited by 33
Ramos, A. T., Troncone, L. R. P., & Tufik, S. (2006) · Neuroendocrinology · doi:10.1159/000097587 · Cited by 33
Attenuated stress-induced catecholamine release in mice lacking the vasopressin V1b receptor
Itoh, S., Yamada, S., Mori, T., Miwa, T., Tottori, K., Uwahodo, Y., Yamamura, Y., Fukuda, M., Yamamoto, K., Tanoue, A., et al. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00005.2006 · Cited by 33
Neurobiological aspects of pain in the context of alcohol use disorder
Cucinello‐Ragland, J. A., & Edwards, S. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.09.001 · Cited by 32
“Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders.”
BackgroundInfluentialPena, A., Murat, B., Trueba, M., Ventura, M. A., Wo, N. C., Szeto, H. H., Cheng, L. L., Stoev, S., Guillon, G., & Manning, M. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm060928n · Cited by 27
The effects of vasopressin deficiency on aggression and impulsiveness in male and female rats
Fodor, A., Barsvári, B., Aliczki, M., Balogh, Z., Zelena, D., Goldberg, S. R., & Haller, J. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.05.010 · Cited by 32
“…behaviors in14 a variety of paradigms and species (maternal aggression15 (Nephew et al., 2010; Bosch and Neumann, 2012); resident-16 intruder test (Cervantes and Delville, 2007; Carrillo et al.,17 2011); predator defense (Griebel et al., 2002); play-fighting18 (Cheng and Delville, 2009)).”
BackgroundDantec, Y. L., Hache, G., Guilloux, J., Guiard, B. P., David, D. J. P., Adrien, J., & Escourrou, P. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.050 · Cited by 32
“This test evaluates the depression-like state of CORT-mice via their grooming capacity by assigning a fur coat state score (Griebel et al., 2002; Santarelli et al., 2003; Surget et al., 2008).”
Bayerl, D. S., Kaczmarek, V., Jurek, B., van den Burg, E. H., Neumann, I. D., Gaßner, B. M., Klampfl, S. M., & Bosch, O. J. (2015) · Hormones and Behavior · doi:10.1016/j.yhbeh.2015.12.003 · Cited by 32
“, 2005); binding of the V1bR antagonist to the structurally similar oxytocin and V1a receptor is rather unlikely as SSR149415 binds with high specificity to the rat V1bR (Griebel et al., 2002; Griffante et al., 2005; Serradeil-LeGal et al., 2002).”
Mathiasen, L., & Mirza, N. R. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0119-z · Cited by 32
“Classical benzodiazepines reduce conflict behaviour in rats in the VCT, as measured by an increase in water intake in the presence of shock delivery (Millan and Brocco 2003; Loiseau et al. 2003; Griebel et al. 1999, 2002; Sorbera et al. 2001; Flores and Pellon 2000; Nazar et al. 1997; Brocco et al. 1990).”
BackgroundKanes, S., Dennie, L., & Perera, P. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s402831 · Cited by 31
Roles of arginine vasotocin receptors in the brain and pituitary of submammalian vertebrates
(2013) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-407696-9.00004-x · Cited by 30
“Analysis of the V1b receptor knockout mouse and pharmacological studies using specific agonists and antagonists have revealed that this receptor is involved in regulating aggression, social memory, and stress responses (Griebel et al., 2002, 2003, 2005; Wersinger et al., 2002, 2004).”
BackgroundHodgson, R. A., Mullins, D., Lu, S. X., Guzzi, M., Zhang, X., Bleickardt, C. J., Scott, J. D., Miller, M. W., Stamford, A. W., Parker, E. M., et al. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.02.027 · Cited by 30
Bayerl, D. S., Klampfl, S. M., & Bosch, O. J. (2014) · Journal of Neuroendocrinology · doi:10.1111/jne.12226 · Cited by 30
Oxytocin and Vasopressin, and the GABA Developmental Shift During Labor and Birth: Friends or Foes?
Ben‐Ari, Y. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00254 · Cited by 30
“AVP receptor antagonists reduce stress and are candidates to treat affective disorders (Griebel et al., 2002).”
BackgroundCudnoch‐Jędrzejewska, A., Szczepanska‐Sadowska, E. K., Dobruch, J. T., Gomolka, R. S., & Puchalska, L. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00543.2009 · Cited by 30
Kamiya, M., Sabia, H. D., Marella, J., Fava, M., Nemeroff, C. B., Umeuchi, H., Iijima, M., Chaki, S., & Nishino, I. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.017 · Cited by 28
Vasopressin in mechanisms of stress reactions and modulation of emotion
Belokoskova, S. G., & Tsikunov, S. G. (2018) · Reviews on Clinical Pharmacology and Drug Therapy · doi:10.17816/rcf1635-12 · Cited by 28
Asymmetric [3+2] annulations of 1,4-di-thiane-2,5-diol and oxindole ketimines
Feng, B., Yang, J., Li, J., & Li, X. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.06.084 · Cited by 28
Gq signaling in α cells is critical for maintaining euglycemia
Liu, L., Dattaroy, D., Simpson, K. F., Barella, L. F., Cui, Y., Xiong, Y., Jin, J. J., König, G. M., Kostenis, E., ROMAN, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.152852 · Cited by 28
“The V1bR agonist-induced increase in glucagon release was prevented by treatment of WT islets with a selective V1bR antagonist (SSR149415; 1 μM) (33), further confirming the involvement of V1bR in this response (Figure 6A, B).”
InfluentialMarston, H. M., Martin, F. D., Papp, M., Gold, L., Wong, E. H., & Shahid, M. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110376684 · Cited by 27
“…using place preference (Muscat et al., 1992), maintenance coat condition (Mineur et al., 2006), plus maze, social avoidance and forced-swim tests (Griebel et al., 2002 a,b; Kompagne et al., 2008), sleep architecture (Cheeta et al., 1997) and intracranial self-stimulation (ICSS) paradigms…”
MethodStemmelin, J., Cohen, C., Yalçın, İ., Keane, P. E., & Griebel, G. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.003 · Cited by 28
Self-citationChen, J., Chen, W., Li, Y., & Xu, M. (2015) · Organic & Biomolecular Chemistry · doi:10.1039/c5ob00063g · Cited by 28
Barsegyan, A., Atsak, P., Hornberger, W., Jacobson, P. B., van Gaalen, M. M., & Roozendaal, B. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.48 · Cited by 27
Zhou, Q.-G., Wu, H.-Y., Zhou, H., Liu, M.-Y., Lee, H. W., Liu, X., Devkota, S., Ro, E., Zhu, D.-Y., & Suh, H. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.106 · Cited by 26
Javadian, N., Rahimi, N., Paydar, M. J., Doustimotlagh, A. H., & Dehpour, A. R. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.07.006 · Cited by 26
Szczepanska‐Sadowska, E. K., Wsół, A., Cudnoch‐Jędrzejewska, A., Czarzasta, K., & Żera, T. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11040908 · Cited by 26
Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography
Schönberger, M., Leggett, C. S., Kim, S. W., & Hooker, J. M. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.108 · Cited by 25
Derick, S., Peña, A., Durroux, T., Wagnon, J., Gal, C. S., Hibert, M., Rognan, D., & Guillon, G. (2004) · Molecular Endocrinology · doi:10.1210/me.2004-0124 · Cited by 25
“zodiazepines or antidepressant drugs (20).”
BackgroundSelf-citationIncreased alcohol consumption in rats after subchronic antidepressant treatment
Alén, F., Orío, L., Gorriti, M. Á., de Heras, R. G., Ramírez-López, M. T., Pozo, M. A., & de Fonseca, F. R. (2013) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000217 · Cited by 24
“In order to assess the possible long-term effects of a treatment with these SSRIs and SNRIs on alcohol consumption in a context of alcohol relapse after a period of abstinence, we selected a model based on the alcohol deprivation effect (ADE: Sinclair and Senter, 1967; Griebel et al., 2002).”
MethodResultPoretti, M. B., Sawant, R. S., Rask‐Andersen, M., de Cúneo, M. F., Schiöth, H. B., Pérez, M. F., & Carlini, V. P. (2015) · Psychopharmacology · doi:10.1007/s00213-015-4187-4 · Cited by 24
Liu, R., Wu, X., He, X., Wang, R.-Z., Yin, X., Zhou, F., Ji, M., & Shen, J.-C. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.173079 · Cited by 24
Discontinued psychiatric drugs in 2008
Kirchhoff, V., Nguyen, H. T., Soczynska, J. K., Woldeyohannes, H. O., & McIntyre, R. S. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903184591 · Cited by 24
“5 SSR-149415 (sanofi-aventis) SSR-149415, an orally-active arginine vasopressin antagonist, was a promising agent under development for the treatment of major depressive disorder and anxiety disorders [10,11].”
Backgroundİşibol, D., Karahan, S., & Tanyeli, C. (2017) · Tetrahedron Letters · doi:10.1016/j.tetlet.2017.12.081 · Cited by 24
Psychotropic and Neurotropic Activity
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_6 · Cited by 24
Balázsfi, D., Pintér, O., Klausz, B., Kovács, K., Fodor, A., Török, B., Engelmann, M., & Zelena, D. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.09.011 · Cited by 23
“Preclinical studies using the first orally active non-peptide V1b antagonist (SSR 149415) resulted in a reduction of floating in the FS test (Griebel et al., 2002).”
BackgroundWerfali, W. M. E., Toomasian, C. J., Maliszewska-Ścisło, M., Li, C., & Rossi, N. F. (2015) · Experimental Physiology · doi:10.1113/expphysiol.2014.084426 · Cited by 23
“Animal studies have implicated V1b receptors within the PVN in stress and depression (Griebel et al. 2002; Tanoue et al. 2004).”
BackgroundJochem, J. (2004) · Inflammation Research · doi:10.1007/s00011-004-1251-7 · Cited by 23
Yayou, K., Ito, S., Kasuya, E., Sutoh, M., Ohkura, S., & OKAMURA, H. (2008) · Journal of Veterinary Medical Science · doi:10.1292/jvms.70.665 · Cited by 23
“Moreover, the V1b receptor has been thought to be involved in the modulatory action of AVP on emotional processes [5].”
BackgroundLinsambarth, S., Moraga‐Amaro, R., Quintana-Donoso, D., Rojas, S., & Stehberg, J. (2017) · InTech eBooks · doi:10.5772/intechopen.68618 · Cited by 23
“AVP released within the brain in general has been pro‐ posed to modulate stress‐induced anxiety [156] and AVP receptor V1b receptor antagonists produce anxiolytic effects on mice [157].”
BackgroundZhou, Y., Rubinstein, M., Low, M. J., & Kreek, M. J. (2017) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.13544 · Cited by 23
“…evidence suggesting thatincreased arginine vasopressin (AVP) neuronal activity represents an important step in the neurobiology of stressrelated behaviors in several rodent models (Griebel et al., 2002; Roper et al., 2011; Salome et al., 2006) and in humans (Katz et al., 2016; Ryan et al., 2017).”
InfluentialLithium, arginine vasopressin and the dex/CRH test in mood disordered patients
Watson, S., Gallagher, P., Smith, M. S., Young, A. H., & Ferrier, I. N. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.02.010 · Cited by 23
“The therapeutic potential of manipulation of the AVP system is of great interest and animal studies have shown that pituitary AVP receptor antagonists reduce anxiety (Griebel et al., 2002; Serradeil-Le Gal et al., 2005).”
BackgroundHigh‐Quality Antidepressant Discovery by Understanding Stress Hormone Physiology
HOLSBOER, F. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1286.038 · Cited by 23
Varga, J., Domokos, Á., Barna, I., Jankord, R., Bagdy, G., & Zelena, D. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.09.014 · Cited by 22
Synthesis of a novel pyrrolo[1,2-c][1.3]benzodiazepine analogue of VPA-985
Rotas, G., Kimbaris, A. C., & Varvounis, G. (2011) · Tetrahedron · doi:10.1016/j.tet.2011.07.083 · Cited by 22
Antiapoptotic effects of vasopressin in the neuronal cell line H32 involve protein kinase Cα and β
Chen, J., Liu, Y., Soh, J., & Aguilera, G. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06219.x · Cited by 22
“As VP is released within the brain during stress and non-peptide V1 antagonists are sought as antidepressant agents (Griebel et al. 2002; Overstreet and Griebel 2005), it is critical to fully understand the mechanisms of the antiapoptotic actions of VP in neuronal cells.”
Background
Metadata
- Authors
- Griebel, G., Simiand, J., Serradeil-Le Gal, C., Wagnon, J., Pascal, M., Scatton, B., Maffrand, J.-P., & Soubrié, P.
- Affiliations
- Sanofi (France) (FR)
- Sanofi–Synthelabo Recherche, Avenue P. V.-Couturier, 92220 Bagneux, France; Sanofi–Synthelabo Recherche, Route d'Espagne, 31100 Toulouse, France; and Sanofi–Synthelabo Recherche, Rue du Professeur Blayac, 34000 Montpellier, France
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2002-04-16
- Volume
- 99
- Issue
- 9
- Pages
- 6370-6375
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC122955
- OpenAlex
- W2003547326
- Cited by
- 471
- References
- 31
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 8 · 2021: 12 · 2020: 14 · 2019: 10 · 2018: 15 · 2017: 8 · 2016: 20 · 2015: 18 · 2014: 29 · 2013: 16 · 2012: 21
- FWCI
- 10.11
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Neuroendocrine regulation and behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- non-peptide antagonists, anxiolytic effects, antidepressant effects, anxiety, depression, chronic mild stress, social defeat, traumatic stress, emotional processing, hypophysectomy, mood disorders
- MeSH terms
- Animals, Antidepressive Agents, Antidepressive Agents, Tricyclic, Anxiety, Behavior, Animal, Depression, Feeding Behavior, Fluoxetine, Imipramine, Indoles, Kinetics, Male, Mice, Inbred BALB C, Pyrrolidines, Stress, Physiological, Stress, Psychological, Time Factors, Anti-Anxiety Agents, Rats, Sprague-Dawley, Rats, Wistar, Risk Assessment, Antidepressive Agents, Second-Generation, Mice, Rats, Antidiuretic Hormone Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.